Technical Analysis for IKNA - Ikena Oncology, Inc.

Grade Last Price % Change Price Change
D 1.50 -4.46% -0.07
IKNA closed down 4.46 percent on Monday, March 18, 2024, on 32 percent of normal volume. It was able to find support at its 50 day moving average.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Flat

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish -4.46%
Crossed Above 50 DMA Bullish -4.46%
MACD Bullish Centerline Cross Bullish -4.46%
Pocket Pivot Bullish Swing Setup -4.46%
Up 3 Days in a Row Strength -4.46%
Crossed Above 20 DMA Bullish 2.74%
Spinning Top Other 6.38%
NR7 Range Contraction 6.38%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 13 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Fell Below 50 DMA about 14 hours ago
Fell Below 10 DMA about 14 hours ago
10 DMA Support about 15 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer

Is IKNA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.6399
52 Week Low 1.02
Average Volume 419,931
200-Day Moving Average 3.55
50-Day Moving Average 1.50
20-Day Moving Average 1.47
10-Day Moving Average 1.50
Average True Range 0.12
RSI (14) 51.22
ADX 13.63
+DI 24.48
-DI 17.62
Chandelier Exit (Long, 3 ATRs) 1.28
Chandelier Exit (Short, 3 ATRs) 1.64
Upper Bollinger Bands 1.63
Lower Bollinger Band 1.30
Percent B (%b) 0.61
BandWidth 22.18
MACD Line 0.00
MACD Signal Line -0.01
MACD Histogram 0.0093
Fundamentals Value
Market Cap 72.39 Million
Num Shares 48.3 Million
EPS -1.62
Price-to-Earnings (P/E) Ratio -0.93
Price-to-Sales 4.84
Price-to-Book 0.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.64
Resistance 3 (R3) 1.65 1.61 1.61
Resistance 2 (R2) 1.61 1.58 1.61 1.60
Resistance 1 (R1) 1.56 1.56 1.54 1.55 1.60
Pivot Point 1.52 1.52 1.52 1.52 1.52
Support 1 (S1) 1.47 1.49 1.45 1.46 1.40
Support 2 (S2) 1.43 1.47 1.43 1.40
Support 3 (S3) 1.38 1.43 1.39
Support 4 (S4) 1.37